SG Americas Securities
PNT

SG Americas Securities’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

SG Americas Securities’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-29,744
Closed -$217K – 3628
2022
Q4 		$217K Buy
29,744
+7,075
+31% +$52.5K ﹤0.01% 2135
2022
Q3 		$175K Buy
22,669
+8,203
+57% +$69.6K ﹤0.01% 2427
2022
Q2 		$99K Buy
+14,466
New +$111K ﹤0.01% 3134

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SG Americas Securities's PNT Position: Q1 2023 in Review

SG Americas Securities sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q1 2023, closing a stake of 29,744 shares — an estimated $217K sold.

SG Americas Securities first reported a position in PNT in Q2 2022 and held it in 3 quarters. The position peaked at $217K in Q4 2022. 115 funds tracked by Wall St. Rank hold PNT as of Q1 2023.

  • SG Americas Securities reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • SG Americas Securities sold 29,744 POINT Biopharma Global Inc. Common Stock shares in Q1 2023, an estimated $217K.
  • SG Americas Securities first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • SG Americas Securities's POINT Biopharma Global Inc. Common Stock position peaked at $217K in Q4 2022.
  • 115 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q1 2023.

Based on SG Americas Securities's 13F filing for Q1 2023, filed 28 Apr 2023.